Sopheon announces that the Company has granted options over 65,000 ordinary shares of 20 pence each in the share capital of the Company (“Options”) to certain directors. These grants are part of a wider grant of 148,778 Options to certain key executives and departmental managers of the Company.
The Options granted will vest over 3 years, and are exercisable up to 10 years from the date of grant. The exercise price of the Options is 565 pence per share, being the mid-market closing price on AIM on Friday 9 February 2018.
Andrew Michuda has been granted 50,000 Options, and Arif Karimjee has been granted 15,000 Options. Following this grant, Andrew Michuda has 290,000 Options in total, and Arif Karimjee has 90,000.
For Further Information Contact:
|Barry Mence, Chairman
Arif Karimjee, CFO
|Sopheon plc||+ 44 (0) 1276 919 560|
|Carl Holmes / Giles Rolls (corporate finance)
Mia Gardener (corporate broking)
|finnCap Ltd||+ 44 (0) 20 7220 0500|
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon’s Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon’s solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange.